Medidata Solutions today announced that Array BioPharma has chosen
Medidata Rave(R) as its enterprise-wide electronic data capture (EDC)
solution. Over a period of three years, Array BioPharma plans to
conduct more than 20 studies using Medidata Rave for Phase I and II
trials in the therapeutic areas of oncology and inflammation.
Established in 1998, Array BioPharma seeks to be the most
efficient inventor of therapeutic products in the pharmaceutical
industry. The biopharmaceutical company focuses specifically on the
discovery, development and commercialization of orally active drugs to
address significant unmet clinical needs. In 2006, Array´s IT
department undertook the task of putting EDC in place as a critical
component to running clinical trials. Array BioPharma comprised a list
of key EDC providers and quickly narrowed it down to a group of five
players. After examining each company´s application services provider
(ASP) model, Array selected two vendors for a technical product
analysis.
Array´s scientific computing group then conducted a year-long
evaluation with input from upper management, and Medidata Solutions
was selected due to the company´s superior product functionality.
Specifically, Array was impressed with the single platform design of
Medidata Rave for EDC and clinical data management, with its ability
to easily pull data for a variety of reporting needs.
"Medidata Rave is an intuitive, easy to use solution - even for
users who were new to the system. Using Rave, clinical research
associates (CRAs) can access data and site information earlier and
become better prepared for more productive site visits. In addition,
Rave´s ability to build forms electronically on our initial trials has
resulted in improved protocol design for clinical study managers,"
said Jim Rizzi, senior director of computational technology at Array
BioPharma. "We have been continually impressed with Medidata´s
corporate culture, the vision of the company´s executives and the
professionalism of its services team. We look forward to improved
results by leveraging Rave as the center of our clinical process."
Array BioPharma plans to use Medidata service offerings to provide
training and help desk support, hosting services and integrations as
well as collaborations, integrating Rave into unique customer tools.
"Array BioPharma is an innovative, forward-thinking company that
stays at the cutting edge of clinical trial development, and we are
excited for the improvements Medidata Rave will bring to Array´s
clinical process," said Tarek Sherif, CEO of Medidata Solutions. "The
company´s enterprise-wide deployment of Medidata Rave speaks to the
rapid acceptance of our technology within the mid-market and the
ability of our team to successfully execute Rave deployments for
sponsors of all sizes."
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat patients afflicted with cancer and
inflammatory diseases. Our proprietary drug development pipeline
includes clinical candidates that are designed to regulate
therapeutically important target proteins and are aimed at large
market opportunities. In addition, leading pharmaceutical and
biotechnology companies collaborate with Array to discover and develop
drug candidates across a broad range of therapeutic areas. For more
information on Array, please go to www.arraybiopharma.com.
About Medidata Solutions Worldwide
Medidata Solutions helps the world´s leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.
